S&P 500   4,217.96 (+0.30%)
DOW   33,070.15 (-0.07%)
QQQ   353.05 (+1.33%)
AAPL   177.98 (+1.45%)
MSFT   333.41 (+0.16%)
META   265.14 (+1.18%)
GOOGL   124.11 (-0.40%)
AMZN   122.54 (+2.02%)
TSLA   204.20 (+5.71%)
NVDA   406.60 (+4.40%)
NIO   7.84 (+1.82%)
BABA   80.33 (-0.79%)
AMD   128.97 (+1.53%)
T   15.47 (-0.19%)
F   12.71 (+5.13%)
MU   73.55 (-0.51%)
CGC   0.87 (-0.59%)
GE   101.50 (-1.21%)
DIS   88.25 (-0.05%)
AMC   4.66 (+0.43%)
PFE   37.11 (-1.30%)
PYPL   60.91 (+1.15%)
NFLX   396.05 (+4.53%)
S&P 500   4,217.96 (+0.30%)
DOW   33,070.15 (-0.07%)
QQQ   353.05 (+1.33%)
AAPL   177.98 (+1.45%)
MSFT   333.41 (+0.16%)
META   265.14 (+1.18%)
GOOGL   124.11 (-0.40%)
AMZN   122.54 (+2.02%)
TSLA   204.20 (+5.71%)
NVDA   406.60 (+4.40%)
NIO   7.84 (+1.82%)
BABA   80.33 (-0.79%)
AMD   128.97 (+1.53%)
T   15.47 (-0.19%)
F   12.71 (+5.13%)
MU   73.55 (-0.51%)
CGC   0.87 (-0.59%)
GE   101.50 (-1.21%)
DIS   88.25 (-0.05%)
AMC   4.66 (+0.43%)
PFE   37.11 (-1.30%)
PYPL   60.91 (+1.15%)
NFLX   396.05 (+4.53%)
S&P 500   4,217.96 (+0.30%)
DOW   33,070.15 (-0.07%)
QQQ   353.05 (+1.33%)
AAPL   177.98 (+1.45%)
MSFT   333.41 (+0.16%)
META   265.14 (+1.18%)
GOOGL   124.11 (-0.40%)
AMZN   122.54 (+2.02%)
TSLA   204.20 (+5.71%)
NVDA   406.60 (+4.40%)
NIO   7.84 (+1.82%)
BABA   80.33 (-0.79%)
AMD   128.97 (+1.53%)
T   15.47 (-0.19%)
F   12.71 (+5.13%)
MU   73.55 (-0.51%)
CGC   0.87 (-0.59%)
GE   101.50 (-1.21%)
DIS   88.25 (-0.05%)
AMC   4.66 (+0.43%)
PFE   37.11 (-1.30%)
PYPL   60.91 (+1.15%)
NFLX   396.05 (+4.53%)
S&P 500   4,217.96 (+0.30%)
DOW   33,070.15 (-0.07%)
QQQ   353.05 (+1.33%)
AAPL   177.98 (+1.45%)
MSFT   333.41 (+0.16%)
META   265.14 (+1.18%)
GOOGL   124.11 (-0.40%)
AMZN   122.54 (+2.02%)
TSLA   204.20 (+5.71%)
NVDA   406.60 (+4.40%)
NIO   7.84 (+1.82%)
BABA   80.33 (-0.79%)
AMD   128.97 (+1.53%)
T   15.47 (-0.19%)
F   12.71 (+5.13%)
MU   73.55 (-0.51%)
CGC   0.87 (-0.59%)
GE   101.50 (-1.21%)
DIS   88.25 (-0.05%)
AMC   4.66 (+0.43%)
PFE   37.11 (-1.30%)
PYPL   60.91 (+1.15%)
NFLX   396.05 (+4.53%)
NYSE:OGN

Organon & Co. (OGN) Stock Forecast, Price & News

$19.23
-0.31 (-1.59%)
(As of 09:45 AM ET)
Compare
Today's Range
$19.18
$19.40
50-Day Range
$19.54
$24.63
52-Week Range
$19.15
$38.61
Volume
132,286 shs
Average Volume
2.10 million shs
Market Capitalization
$4.90 billion
P/E Ratio
6.59
Dividend Yield
5.82%
Price Target
$29.00

Organon & Co. MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
48.4% Upside
$29.00 Price Target
Short Interest
Healthy
2.71% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.32
Upright™ Environmental Score
News Sentiment
0.73mentions of Organon & Co. in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
8.33%
From $4.20 to $4.55 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.11 out of 5 stars

Medical Sector

20th out of 1,009 stocks

Pharmaceutical Preparations Industry

7th out of 494 stocks


OGN stock logo

About Organon & Co. (NYSE:OGN) Stock

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

Receive OGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter.

OGN Stock News Headlines

Why Organon & Co. Is A Smart Investment
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
Organon's Earnings: A Preview
Organon & Co. (OGN) Scheduled to Post Earnings on Thursday
Organon: A Bitter Pill
Morgan Stanley Reaffirms Their Hold Rating on Organon (OGN)
Organon & Co (OGN) Q4 2022 Earnings Call Transcript
Why Shares of Organon Fell 15% Thursday
Organon Shares Drop 14% After 4Q Earnings Miss
See More Headlines
Receive OGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter.

OGN Company Calendar

Ex-Dividend for 3/16 Dividend
2/24/2023
Dividend Payable
3/16/2023
Last Earnings
5/04/2023
Ex-Dividend for 6/15 Dividend
5/12/2023
Today
5/30/2023
Dividend Payable
6/15/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
10,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$29.00
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+50.8%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$917 million
Pretax Margin
14.89%

Debt

Sales & Book Value

Annual Sales
$6.17 billion
Cash Flow
$5.79 per share
Book Value
($3.51) per share

Miscellaneous

Free Float
254,985,000
Market Cap
$4.90 billion
Optionable
Not Optionable
Beta
0.77

Key Executives

  • Mr. Kevin Ali (Age 63)
    CEO & Director
    Comp: $3.08M
  • Mr. Matthew M. Walsh (Age 56)
    Exec. VP & CFO
    Comp: $1.57M
  • Ms. Susanne Gabriele Fiedler (Age 55)
    Exec. VP & Chief Commercial Officer
    Comp: $1.51M
  • Dr. Sandra Milligan J.D. (Age 59)
    M.D., Exec. VP and Head of R&D
    Comp: $1.21M
  • Ms. Rachel A. Stahler (Age 47)
    Exec. VP & Chief Information Officer
  • Ms. Jennifer Halchak
    VP of Investor Relations
  • Mr. Kirke Weaver
    Gen. Counsel & Corp. Sec.
  • Mr. Aaron Falcione (Age 52)
    Exec. VP & Chief HR Officer
  • Mr. Joseph T. Morrissey Jr. (Age 58)
    Exec. VP and Head of Manufacturing & Supply
  • Mr. Vittorio Nisita (Age 55)
    Exec. VP & Head of Global Bus. Services













OGN Stock - Frequently Asked Questions

Should I buy or sell Organon & Co. stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organon & Co. in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" OGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OGN, but not buy additional shares or sell existing shares.
View OGN analyst ratings
or view top-rated stocks.

What is Organon & Co.'s stock price forecast for 2023?

4 brokers have issued 12 month target prices for Organon & Co.'s shares. Their OGN share price forecasts range from $24.00 to $34.00. On average, they anticipate the company's share price to reach $29.00 in the next twelve months. This suggests a possible upside of 50.8% from the stock's current price.
View analysts price targets for OGN
or view top-rated stocks among Wall Street analysts.

How have OGN shares performed in 2023?

Organon & Co.'s stock was trading at $27.93 at the beginning of 2023. Since then, OGN shares have decreased by 31.1% and is now trading at $19.23.
View the best growth stocks for 2023 here
.

When is Organon & Co.'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our OGN earnings forecast
.

How were Organon & Co.'s earnings last quarter?

Organon & Co. (NYSE:OGN) released its earnings results on Thursday, May, 4th. The company reported $1.08 EPS for the quarter, missing the consensus estimate of $1.18 by $0.10. The firm had revenue of $1.54 billion for the quarter, compared to analysts' expectations of $1.54 billion. Organon & Co. had a net margin of 12.14% and a negative trailing twelve-month return on equity of 119.00%. The business's revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the prior year, the business earned $1.65 earnings per share.
Read the conference call transcript
.

How often does Organon & Co. pay dividends? What is the dividend yield for Organon & Co.?

Organon & Co. announced a quarterly dividend on Thursday, May 4th. Stockholders of record on Monday, May 15th will be given a dividend of $0.28 per share on Thursday, June 15th. This represents a $1.12 dividend on an annualized basis and a yield of 5.82%. The ex-dividend date is Friday, May 12th.
Read our dividend analysis for OGN
.

Is Organon & Co. a good dividend stock?

Organon & Co. (NYSE:OGN) pays an annual dividend of $1.12 per share and currently has a dividend yield of 5.73%. OGN has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 38.36%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, OGN will have a dividend payout ratio of 24.62% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for OGN.

What guidance has Organon & Co. issued on next quarter's earnings?

Organon & Co. updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $6.15 billion-$6.45 billion, compared to the consensus revenue estimate of $6.29 billion.

What is Organon & Co.'s stock symbol?

Organon & Co. trades on the New York Stock Exchange (NYSE) under the ticker symbol "OGN."

Who are Organon & Co.'s major shareholders?

Organon & Co.'s stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.36%), Mawer Investment Management Ltd. (5.20%), State Street Corp (5.03%), Bank of New York Mellon Corp (2.14%), Geode Capital Management LLC (2.13%) and Sound Shore Management Inc. CT (1.31%).
View institutional ownership trends
.

How do I buy shares of Organon & Co.?

Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Organon & Co.'s stock price today?

One share of OGN stock can currently be purchased for approximately $19.23.

How much money does Organon & Co. make?

Organon & Co. (NYSE:OGN) has a market capitalization of $4.90 billion and generates $6.17 billion in revenue each year. The company earns $917 million in net income (profit) each year or $2.92 on an earnings per share basis.

How many employees does Organon & Co. have?

The company employs 10,000 workers across the globe.

How can I contact Organon & Co.?

Organon & Co.'s mailing address is 2000 Galloping Hill Road, Kenilworth, New Jersey 07033. The official website for the company is www.organon.com. The company can be reached via phone at 551-430-6900 or via email at investor_relations@organon.com.

This page (NYSE:OGN) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -